To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

February 18, 2022

Study Completion Date

October 18, 2022

Conditions
Solid Tumor
Interventions
OTHER

High-fat meal (over 900 kcal)

High-fat meal (over 900 kcal with over 35 percent fat content of total calorie) will be provided prior to IP administration. The IP will then be administered 30 minutes after the subject begins the meal.

DRUG

ABN401 (investigational product)

The investigational product, ABN401 800 mg (3 x 250 mg + 2 x 25 mg) will be administered orally with approximately 240 mL of water in fasted or fed condition in accordance with the order of IP administration in an allocated sequence.

Trial Locations (1)

Unknown

Chungbuk National University Hospital, Cheongju-si

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abion Inc

INDUSTRY

NCT05248074 - To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter